Enhancing Checkpoint Inhibitors in Triple-Negative Breast Cancer Presented By Kevin Kalinsky at 2018 ASCO Annual Meeting.

Presentación del tema: "Enhancing Checkpoint Inhibitors in Triple-Negative Breast Cancer Presented By Kevin Kalinsky at 2018 ASCO Annual Meeting."— Transcripción de la presentación:

1 Enhancing Checkpoint Inhibitors in Triple-Negative Breast Cancer Presented By Kevin Kalinsky at 2018 ASCO Annual Meeting

2 Disclosures Presented By Kevin Kalinsky at 2018 ASCO Annual Meeting

3 Low Response Rates with Chemotherapy in Metastatic TNBC Presented By Kevin Kalinsky at 2018 ASCO Annual Meeting

4 TIL Expression as a Prognostic Marker Presented By Kevin Kalinsky at 2018 ASCO Annual Meeting

5 Variability in Response to Single Agent Checkpoint Inhibitors Presented By Kevin Kalinsky at 2018 ASCO Annual Meeting

6 Response Associates with Improved OS to Checkpoint Inhibitors Presented By Kevin Kalinsky at 2018 ASCO Annual Meeting

7 Combination Strategies to Enhance Immunogenicity? Presented By Kevin Kalinsky at 2018 ASCO Annual Meeting

8 Olympiad Trial: Parp Inhibitors Presented By Kevin Kalinsky at 2018 ASCO Annual Meeting

9 Rationale for Parp + Checkpoint Inhibitors Presented By Kevin Kalinsky at 2018 ASCO Annual Meeting

10 Open-label, multi-tumor, Phase II basket study of olaparib and durvalumab (MEDIOLA): Germline BRCA-mutated HER2- MBC Presented By Kevin Kalinsky at 2018 ASCO Annual Meeting

11 MEDIOLA: Olaparib + Durvalumab (n=25) Presented By Kevin Kalinsky at 2018 ASCO Annual Meeting

12 TOPACIO: Niraparib + Pembrolizumab (n=46) Presented By Kevin Kalinsky at 2018 ASCO Annual Meeting

13 Rationale for Chemotherapy or XRT + Checkpoint Inhibitor Presented By Kevin Kalinsky at 2018 ASCO Annual Meeting

14 Concomitant Chemotherapy + Checkpoint Inhibitor Presented By Kevin Kalinsky at 2018 ASCO Annual Meeting

15 Operable Setting: Pathologic Response in ISPY2 Presented By Kevin Kalinsky at 2018 ASCO Annual Meeting

16 TONIC Trial: Induction Tx + Nivolumab (n=66) Presented By Kevin Kalinsky at 2018 ASCO Annual Meeting

17 TOPACIO and TONIC Trials Presented By Kevin Kalinsky at 2018 ASCO Annual Meeting

18 Future Directions? Presented By Kevin Kalinsky at 2018 ASCO Annual Meeting

19 Parp inhibitor + Checkpoint Inhibitor Presented By Kevin Kalinsky at 2018 ASCO Annual Meeting

20 Chemotherapy + Checkpoint Inhibitor Presented By Kevin Kalinsky at 2018 ASCO Annual Meeting

21 Trials in the Operable Setting Presented By Kevin Kalinsky at 2018 ASCO Annual Meeting

22 Potential Targets in Cancer-Immunity Cycle Presented By Kevin Kalinsky at 2018 ASCO Annual Meeting

23 Summary Presented By Kevin Kalinsky at 2018 ASCO Annual Meeting